Related references
Note: Only part of the references are listed.Preparation and Evaluation of Colon-Targeted Prodrugs of the Microbial Metabolite 3-Indolepropionic Acid as an Anticolitic Agent
Hanju Lee et al.
MOLECULAR PHARMACEUTICS (2021)
Dapsone Ameliorates Colitis through TLR4/NF-kB Pathway in TNBS Induced Colitis Model in Rat
Razieh Mohammad Jafari et al.
ARCHIVES OF MEDICAL RESEARCH (2021)
A Colon-Targeted Prodrug, 4-Phenylbutyric Acid-Glutamic Acid Conjugate, Ameliorates 2,4-Dinitrobenzenesulfonic Acid-Induced Colitis in Rats
Soojin Kim et al.
PHARMACEUTICS (2020)
Mesalazine Activates Adenosine Monophosphate-Activated Protein Kinase: Implication in the Anti-Inflammatory Activity of this Anti-Colitic Drug
Heejung Park et al.
CURRENT MOLECULAR PHARMACOLOGY (2019)
Dapsone reduced acetic acid-induced inflammatory response in rat colon tissue through inhibition of NF-kB signaling pathway
Amir Rashidian et al.
IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY (2019)
A review on 5-aminosalicylic acid colon-targeted oral drug delivery systems
Hossein Shahdadi Sardo et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2019)
Conventional drug therapy for inflammatory bowel disease
Robert V. Bryant et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2015)
Dapsone in dermatology and beyond
Gottfried Wozel et al.
ARCHIVES OF DERMATOLOGICAL RESEARCH (2014)
Inflammatory Bowel Disease: Etiology, Pathogenesis and Current Therapy
Joshua K. Ko et al.
CURRENT PHARMACEUTICAL DESIGN (2014)
Treatment of inflammatory bowel disease (IBD)
Anand B. Pithadia et al.
PHARMACOLOGICAL REPORTS (2011)
Optimizing clinical use of mesalazine (5-aminosalicylic acid) in inflammatory bowel disease
Chadwick Williams et al.
Therapeutic Advances in Gastroenterology (2011)
Mesalazine in inflammatory bowel disease: A trendy topic once again?
Marietta Iacucci et al.
CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2010)
What should be considered on design of a colon-specific prodrug?
Yunjin Jung et al.
EXPERT OPINION ON DRUG DELIVERY (2010)
Unravelling the pathogenesis of inflammatory bowel disease
R. J. Xavier et al.
NATURE (2007)
Review article: high-dose aminosalicylates to induce and maintain remissions in ulcerative colitis
S. B. Hanauer
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2006)
Review article: maintenance therapy in patients with ulcerative colitis
T. Orchard et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2006)
Synthesis and evaluation of analogues of congo red as potential compounds against transmissible spongiform. encephalopathies
H Rudyk et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2003)
The pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis
WJ Sandborn et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2003)
Colonic drug delivery: Prodrug approach
VR Sinha et al.
PHARMACEUTICAL RESEARCH (2001)
Screening Congo Red and its analogues for their ability to prevent the formation of PrP-res in scrapie-infected cells
H Rudyk et al.
JOURNAL OF GENERAL VIROLOGY (2000)